Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Biologics, with their precision targeting, expand treatment options for a multitude of diseases - from cancer to autoimmune disorders. In 2023 alone, 10 antibody therapeutics received their first ...

While humanized animal models are relatively new to drug development compared to their non-humanized counterparts, they are critical tools in the landscape of biologic drug development. Their success ...

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

While many headline-grabbing biologics and advanced therapeutics like cell and gene therapies are approved as injectables, CDMOs Bora Pharmaceuticals and Corealis Pharma understand that oral solid ...

The two drug candidates that AbCellera Biologics is developing have reached Phase 1 of clinical trials, but it will require years to be commercialized if they are developed successfully. None of the ...

"FDA and EMA release collaborative AI framework for drug development" was originally created and published by Clinical Trials ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

In Darwinian terms, survival isn’t a matter of being the biggest, the fastest, or the strongest of the species, but instead ...